Experience

Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China Biologic”) in connection with the going-private acquisition of China…

Davis Polk advised the initial purchasers in connection with a $350 million Regulation S offering by CIFI Holdings (Group) Co. Ltd. of its 5.250% senior notes due 2026. Concurrently with…

Davis Polk advised the joint lead managers and joint bookrunners in connection with an issuance of $500 million Regulation S offering by Yili Holding Investment Limited of its 1.625%…

Davis Polk advised the joint lead managers in connection with the offering of the $400 million 2.437% bonds due 2023 by Shangdong Hi-Speed Group (Hong Kong) Co., Limited with the benefit of…

Davis Polk advised the underwriter in connection with an SEC-registered secondary offering of 1,400,000 shares of Veritiv Corporation’s common stock by UWW Holdings, LLC. The common…

Davis Polk advised the book-running manager on an SEC-registered offering by General Motors Financial Company, Inc. of its $750 million aggregate principal amount of its floating-rate…

Davis Polk advised LendingTree, Inc. in connection with the $872 million secondary offering of 2,955,984 shares of its common stock by Ventures Holdco II, LLC, which is a wholly owned…

Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an approximately $173.8 million public offering of common stock by…

Davis Polk advised Morgan Stanley on the recommencement of its SEC-registered financing programs and the related filing of its universal shelf registration statement, which includes a…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering by Pacific Gas and Electric Company of $1.45 billion aggregate…